VIBER
Viber (www.viber.com ), the pioneering mobile communications platform offering free messaging, HD-quality phone and video calls, unveiled a new version of its app today at Microsoft Build in San Francisco. Viber’s new design is fully optimized for Windows 10’s responsive OS, creating a well-integrated product that blends seamlessly into the user experience of Windows 10.
During the keynote presentation, a demonstration showed how Cortana voice commands could be used to send Viber messages and to start chatting with contacts quickly. Attendees will also be shown deep integration of Viber contact card data within the platform, allowing users to send messages and make voice and video calls via Viber more easily.
The app will work smoothly across PC, tablet and mobile, resizing and adapting the on-screen content to optimize the experience even as the window size changes. Integration with Live Tiles enables users to pin Viber, or a specific chat, to the start menu allowing them to see notifications from Viber even before opening the app, and through actionable notifications Viber users can respond to a message immediately without exiting their current task.
“We’re really excited about Windows 10 and the opportunities it offers to developers,” said Michael Shmilov, Viber’s COO. “The Universal Windows Platform has allowed us to create a unique version of Viber that lets users switch to the device that suits them at any given moment and stay in complete sync, without compromising their experience. Beyond that, the integration with Live Tiles and Cortana, plus the social extensibility that Windows 10 offers will enhance the way people communicate with Viber. We will keep working closely with Microsoft in order to ensure the best possible experience for Viber users on Windows 10.”
“As one of the first chat apps to embrace Windows 10, Viber has taken advantage of new OS features to enhance a user’s communications experience on any Windows device ,” said Steven Guggenheimer, Corporate Vice President and Chief Evangelist at Microsoft. “Today’s demos have highlighted how our investments in the Universal Windows Platform empower partners to deliver innovation and choice to their users, through the breadth of all Windows 10 devices.”
Viber for Windows 10 will be available later this year.
About Viber:
Viber, the pioneering mobile messaging, voice and video service, lets everyone in the world connect. Freely. Users can send free text messages, fun stickers, photos, videos and doodles, share locations, make free HD-quality calls and communicate with Push-To-Talk. With Viber Out, users can make low-cost calls to any phone number worldwide. Viber is available for iPhone®, Android™ phones and tablets, Windows Phone, BlackBerry®, Blackberry® 10, Windows®, Windows 8®, Mac, Linux and Symbian devices over 3G/4G or WiFi connections. With over 516 million unique users in 193 countries, Viber is constantly innovating by introducing new platforms and adding fun new features. Viber is a Rakuten Group company.
Contact:
Viber Media:
Blonde 2.0 for Viber
Jonah Balfour, 1-917-675-3245
Jonah@blonde20.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum